IDR-1018 

IDR-1018 is an innate defense regulator conjugate, with MICs of 16 μg/mL for MRSA USA300 LAC, MRSA SAP 0017 and S. epidermidis ATCC14990. IDR-1018 can be used to synthesis V-IDR1018 (vancomycin-innate defense regulator conjugate)^[1][2].

IDR-1018 modulates the expression of neutrophil adhesion and activation markers^[3].
IDR-1018 is the most potent inducer of chemokines to date and demonstrates anti-infective and anti-inflammatory activity in mouse models, including efficacy in treating Plasmodium berghei ANKA cerebral malaria when administered in conjunction with standard first-line antimalarials^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1535.93

C₇₁H₁₂₆N₂₆O₁₂

1453221-07-2

Val-Arg-Leu-Ile-Val-Ala-Val-Arg-Ile-Trp-Arg-Arg-NH2

VRLIVAVRIWRR-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hashem Etayash, Multifunctional Antibiotic–Host Defense Peptide Conjugate Kills Bacteria, Eradicates Biofilms, and Modulates the Innate Immune Response. J. Med. Chem. 2021, 64, 22, 16854-16863.

  [2]. Hashem Etayash, et al. Correction to “Multifunctional Antibiotic–Host Defense Peptide Conjugate Kills Bacteria, Eradicates Biofilms, and Modulates the Innate Immune Response”. J. Med. Chem. 2022, 65, 3, 2710-2711.

  [3]. François Niyonsaba, et al. The innate defense regulator peptides IDR-HH2, IDR-1002, and IDR-1018 modulate human neutrophil functions. J Leukoc Biol. 2013 Jul;94(1):159-70.  [Content Brief]